Boundless Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Cash & Equivalents	24.27	11.48
Short-Term Investments	97.05	55.77
Cash & Cash Equivalents	121.31	67.25
Cash Growth	80.39%	-
Other Current Assets	2.89	0.79
Total Current Assets	124.2	68.04
Property, Plant & Equipment	4.58	7.73
Other Long-Term Assets	1.12	1.07
Total Long-Term Assets	5.69	8.79
Total Assets	129.89	76.83
Accounts Payable	4.27	2.84
Current Debt	2.2	2.34
Other Current Liabilities	2.9	2.55
Total Current Liabilities	9.36	7.73
Long-Term Debt	0	2.85
Other Long-Term Liabilities	247.62	0.01
Total Long-Term Liabilities	247.62	2.85
Total Liabilities	256.98	10.58
Total Debt	2.2	5.18
Debt Growth	-57.65%	-
Retained Earnings	-136.11	-86.68
Comprehensive Income	0.04	-0.4
Shareholders' Equity	-127.08	-81.7
Net Cash / Debt	119.12	62.07
Net Cash / Debt Growth	91.92%	-
Net Cash Per Share	97.96	56.53
Working Capital	114.85	60.31
Book Value Per Share	-104.51	-74.40

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).